Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

hepatitis b/cefaleia

O link é salvo na área de transferência
Página 1 a partir de 96 resultados

Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
OBJECTIVE To review long-term safety data from the rollover study ETV-901, focusing on adverse events (AEs) with a potential nucleos(t)ide association. METHODS The open-label study ETV-901 (AI463901) assessed the safety of entecavir in chronic hepatitis B patients who received entecavir, lamivudine
OBJECTIVE To study safety and immunogenicity of concomitant administration of hepatitis B (HB), Tetanus-diphtheria (Td), and Measles-mumps-rubella (MMR) vaccines in healthy 11-12-year-olds. METHODS One hundred ninety-seven healthy 11-12-year-olds from the general community were randomized in an
Nine patients with chronic hepatitis type B were treated with recombinant interleukin 2 (rIL-2). Side effects were limited to low-grade fever and headache, which were transient and tolerable for the patients. Seven normal volunteers and nine patients with chronic active hepatitis were administered

Schistosomiasis japonicum diagnosed on liver biopsy in a patient with hepatitis B co-infection: a case report.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND Chronic hepatitis B virus and schistosomiasis are independently associated with significant mortality and morbidity worldwide. Despite much geographic overlap between these conditions and no reason why co-infection should not exist, we present what is, to the best of our knowledge, the

Clinical evaluation of a yeast recombinant hepatitis B vaccine in healthy hospital staff in Singapore.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
A yeast recombinant hepatitis B vaccine (subtype adw), derived from purification of HBsAg particles, expressed in the yeast Saccharomyces cerevisiae which contained the gene for HBsAg, was evaluated in 31 healthy adult hospital staff members in Singapore. Each subject received a 10 mcg dose of

Human plasma derived hepatitis B vaccine: Kenyan experience.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
OBJECTIVE To determine the efficacy and safety of hepaccine B. METHODS Vaccination on first-come-first-served basis. METHODS Kenya Medical Research Institute (KEMRI) staff and families at Nairobi, Kenya. METHODS A total of 107 vaccinees aged 0-10 years and 10 years and above. RESULTS Antibody to

Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Hepatitis B and its sequelae are a major public health problem. Vaccines have been available for almost 20 years; however the disease still remains a global problem. Many factors contribute to the failure to control hepatitis B, including the limited nature of the vaccination programs implemented

Telbivudine for the management of chronic hepatitis B virus infection.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND Telbivudine (LdT) is an L-nucleoside that is structurally related to lamivudine. It is highly selective for hepatitis B virus (HBV) and inhibits viral DNA synthesis. LdT was approved by the US Food and Drug Administration on October 25, 2006, for the treatment of chronic HBV infection in

[A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient].

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Entecavir (Baraclude®) is an oral antiviral drug used for the treatment of HBV. Entecavir is a reverse transcriptase inhibitor which prevents the HBV from multiplying. Most common adverse reactions caused by entecavir are headache, fatigue, dizziness, and nausea. Until now, there has been no report
Antiviral treatment is currently not recommended for patients with chronic hepatitis B with a low viral load. However, they might benefit from acquiring a functional cure (hepatitis B surface antigen [HBsAg] loss with or without formation of antibodies against hepatitis B surface antigen
Nucleotide/nucleoside analogues (antiviral therapy) are used in the therapy of HBeAg positive and HBeAg negative chronic hepatitis B. We analyzed ten selected randomized controlled with 2557 patients to estimate the effect of antiviral drugs in chronic hepatitis B with compared to placebo.

Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Aggressive administration of hepatitis B immune globulin (HBIg) has been shown to prevent hepatitis B viral (HBV) infection of the allograft; however, the clinical sequela of such therapy has not been previously described. We reviewed our experience with high dose, intravenous infusion of an
BACKGROUND The nasal vaccine candidate (NASVAC), comprising hepatitis B virus (HBV) surface (HBsAg) and core antigens (HBcAg), has been shown to be highly immunogenic in animal models. METHODS A phase I double-blinded, placebo-controlled randomized clinical trial was carried out in 19 healthy male
Fusidic acid (FA) is an active agent against gram-positive bacteria such as Staphylococcus, it is generally well tolerated and the major adverse effects are mild gastrointestinal discomfort, diarrhea, and headache. However, some rare side effects such as granulocytopenia and
OBJECTIVE To assess the clinical effectiveness and cost-effectiveness of adefovirdipivoxil (ADV) and pegylated interferon alfa-2a (PEG) for the treatment of adults with chronic hepatitis B infection (CHB). METHODS Electronic databases for the period from 1995-6 to April 2005. Websites of the
Junte-se à nossa
página do facebook

O mais completo banco de dados de ervas medicinais apoiado pela ciência

  • Funciona em 55 idiomas
  • Curas herbais apoiadas pela ciência
  • Reconhecimento de ervas por imagem
  • Mapa GPS interativo - marcar ervas no local (em breve)
  • Leia publicações científicas relacionadas à sua pesquisa
  • Pesquise ervas medicinais por seus efeitos
  • Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas

Google Play badgeApp Store badge